Relationships Between Thyroid Hormones, Insulin-Like Growth Factor-1 and Antioxidant Levels in Hypothalamic Amenorrhea and Impact on Bone Metabolism

Abstract

Reduced bone mineral density (BMD) in Functional Hypothalamic Amenorrhea (FHA) is mainly related to hypoestrogenism, but other hormonal derangement (reduced conversion of T4–T3 and GH resistance) can play a role. These hormones are involved in antioxidant systems regulation. We evaluated the impact of hormonal alterations, with special focus on low T3 and IGF-1 levels, on antioxidant systems as a link with osteoporosis in FHA. Forty-three FHA patients, 15–34 years, with BMI range 17.3–23.4 kg/m², were divided in 2 groups according to fT3 levels; group A (n=22), low fT3 (<2.4 pg/ml) and group B (n=21), normal fT3 (≥ 2.4 pg/ml). We evaluated hormonal parameters (fT3, fT4, TSH, IGF-1, FSH, LH, estradiol, DHEAS, testosterone, cortisol), bone metabolism (calcium, phosphorus, 25-OH Vitamin D, PTH, β-crosslaps, bone alkaline phosphatase) and total antioxidant capacity (TAC), expressed as LAG (latency time in radical species appearance using spectrophotometric method). BMD was assessed by DEXA. Group A patients exhibited significantly lower levels of IGF-1 (159.76±14.79 vs. 220.05±15.25 ng/ml) and osteocalcin (17.51±1.14 vs. 21.49±1.56 ng/ml); LAG values were significantly higher in A (66.33±1.74 s) vs. B (54.62±1.74 s). A significant direct correlation was found between both IGF-1 and fT3 with osteocalcin (r²=0.22, p=0.0049 and r²=0.34, p=0.0001, respectively). No difference in LAG between groups according to IGF-1 were found. These data show a correlation between altered bone turnover and low fT3, which is highly prevalent in FHA. Low fT3 levels may contribute to reduced BMD. Oxidative stress could be the link underlying different bone turnover pattern and endocrine dysfunction in FHA.

Key words

amenorrhea - osteoporosis - non-thyroidal illness - osteocalcin - antioxidants

• References

• 1 The Practice Committee of the American Society for Reproductive Medicine . Current evaluation of amenorrhea. 2008 Compend Pract Comm Reports 2008; 90: S219-S225
• 2 Gordon CM, Ackerman KE, Berga SL. et al. Functional hypothalamic amenorrhea: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2017; 102: 1413-1439
• 3 Berga SL, Mortola JF, Girton L. et al. Neuroendocrine aberrations in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab 1989; 68: 301-308
• 4 Meczekalski B, Podfigurna-Stopa A, Warenik-Szymankiewicz A. et al. Functional hypothalamic amenorrhea: Current view on neuroendocrine aberrations. Gynecol Endocrinol 2008; 24: 4-11
• 5 Meczekalski B, Katulski K, Czyzyk A. et al. Functional hypothalamic amenorrhea and its influence on women’s health. J Endocrinol Invest 2014; 37: 1049-1056
• 6 Berga SL, Daniels TL, Giles DE. Women with functional hypothalamic amenorrhea but not other forms of anovulation display amplified cortisol concentrations. Fertil Steril 1997; 67: 1024-1030
• 7 Laughlin GA, Dominguez CE, Yen SSC. Nutritional and endocrine-metabolic aberrations in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab 1998; 83: 25-32
• 8 Kavushansky A, Kritman M, Maroun M. et al. β-Endorphin degradation and the individual reactivity to traumatic stress. Eur Neuropsychopharmacol 2013; 23: 1779-1788
• 9 Bérubé P, Laforest S, Bhatnagar S. et al. Enkephalin and dynorphin mRNA expression are associated with resilience or vulnerability to chronic social defeat stress. Physiol Behav 2013; 122: 237-245
• 10 Kling JM, Clarke BL, Sandhu NP. Osteoporosis prevention, screening, and treatment: A review. J Womens Health (Larchmt) 2014; 23: 563-572
• 11 De Souza MJ, Williams NI. Physiological aspects and clinical sequelae of energy deficiency and hypoestrogenism in exercising women. Hum Reprod Update 2004; 10: 433-448
• 12 Khosla S. Update on estrogens and the skeleton. J Clin Endocrinol Metab 2010; 95: 3569-3577
• 13 Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002; 359: 1841-1850
• 14 Halliwell B, Gutteridge JMC. Free Radicals in Biology and Mededicine. In Halliwell B, Gutteridge JMC. (Eds.). Free radicals in biology and medicine. 3rd Edition Oxford University Press; Oxford: 1999: 1-25
• 15 Manolagas SC. From estrogen-centric to aging and oxidative stress: A revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010; 31: 266-300
• 16 Mancini A, Festa R, Di Donna V. et al. Hormones and antioxidant systems: Role of pituitary and pituitary-dependent axes. J Endocrinol Invest 2010; 33: 422-433
• 17 American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders DSM-V. Washington D. C.: 2013
• 18 Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Methods Enzymol 1994; 234: 279-293
• 19 Mancini A, Leone E, Festa R. et al. Evaluation of antioxidant systems (coenzyme Q10 and total antioxidant capacity) in morbid obesity before and after biliopancreatic diversion. Metabolism 2008; 57: 1384-1389
• 20 Baroncelli GI, Bertelloni S, Sodini F. et al. Osteoporosis in children and adolescents etiology and management. Pediatr Drugs 2005; 7: 295-323
• 21 Mancini A, Di Segni C, Raimondo S. et al. Thyroid hormones, oxidative stress, and inflammation. Mediators Inflamm 2016; Article ID 6757154 http://dx.doi.org/10.1155/2016/6757154
• 22 Misra M, Klibanski A. Anorexia nervosa and bone. J Endocrinol 2014; 221: R163-R176
• 23 Ohlsson C, Mellström D, Carlzon D. et al. Older men with low serum IGF-1 have an increased risk of incident fractures: The MrOS Sweden study. J Bone Miner Res 2011; 26: 865-872
• 24 Sugimoto T, Nishiyama K, Kuribayashi F. Serum levels of insulin-like growth factor (IGF) I , osteoporotic patients with and without spinal fractures. J Bone Min Res 1997; 12: 1272-1279
• 25 Locatelli V, Bianchi VE. Effect of GH/IGF-1 on bone metabolism and osteoporsosis. Int J Endocrinol 2014; 2014 235060 doi:10.1155/2014/235060
• 26 Vandenput L, Boonen S, Van Herck E. et al. Evidence from the aged orchidectomized male rat model that 17β-estradiol is a more effective bone-sparing and anabolic agent than 5α-dihydrotestosterone. J Bone Miner Res 2002; 17: 2080-2086
• 27 Fazeli PK, Klibanski A. Anorexia nervosa and bone metabolism. Bone 2014; 66: 39-45
• 28 Wang Y, Bikle DD, Chang W. Autocrine and paracrine actions of IGF-I signaling in skeletal development. Bone Res 2013; 1: 249-259
• 29 Ghodsi M, larijani B, Keshtkar AA. et al. Mechanisms involved in altered bone metabolism in diabetes: A narrative review. J Diabetes Metab Disord 2016; 15: 52
• 30 Tripathi T, Gupta P, Rai P. et al. Osteocalcin and serum insulin-like growth factor-1 as biochemical skeletal maturity indicators. Prog Orthod 2017; 18: 30
• 31 Abu EO, Bord S, Horner A. et al. The expression of thyroid hormone receptors in human bone. Bone 1997; 21: 137-142
• 32 Kindblom JM, Gevers EF, Skrtic SM. et al. Increased adipogenesis in bone marrow but decreased bone mineral density in mice devoid of thyroid hormone receptors. Bone 2005; 36: 607-616
• 33 Williams GR. Thyroid hormone actions in cartilage and bone. Eur Thyroid J 2012; 3-13
• 34 Xing W, Govoni KE, Donahue LR. et al. Genetic evidence that thyroid hormone is indispensable for prepubertal insulin-like growth factor-I expression and bone acquisition in mice. J Bone Miner Res 2012; 27: 1067-1079
• 35 Milne M, Quail JM, Rosen CJ. et al. Insulin-like growth factor binding proteins in femoral and vertebral bone marrow stromal cells: expression and regulation by thyroid hormone and dexamethasone. J Cell Biochem 2001; 81: 229-240
• 36 Stevens DA, Harvey CB, Scott AJ. et al. Thyroid hormone activates fibroblast growth factor receptor-1 in bone. Mol Endocrinol 2003; 17: 1751-1766
• 37 Varga F, Rumpler M, Zoehrer R. et al. T3 affects expression of collagen I and collagen cross-linking in bone cell cultures. Biochem Biophys Res Commun 2010; 402: 180-185
• 38 Gouveia CH, Schultz JJ, Bianco AC. et al. Thyroid hormone stimulation of osteocalcin gene expression in ROS 17/2.8 cells is mediated by transcriptional and post-transcriptional mechanisms. J Endocrinol 2001; 170: 667-675
• 39 Bassett JHD, Boyde A, Howell PGT. et al. Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts. Proc Natl Acad Sci USA 2010; 107: 7604-7609
• 40 Mastorakos G, Pavlatou M. Exercise as a stress model and the interplay between the hypothalamus-pituitary-adrenal and the hypothalamus-pituitary-thyroid axes. Horm Metab Res 2005; 37: 577-584
• 41 Riggs BL. The mechanisms of estrogen regulation of bone resorption. J Clin Invest 2000; 106: 1203-1204
• 42 Mircea CN, Lujan ME, Pierson RA. Metabolic fuel and clinical implications for female reproduction. J Obstet Gynaecol Canada 2007; 29: 887-902
• 43 Mödder UIl, Clowes JA, Hoey K. et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 2011; 26: 27-34
• 44 Fazeli PK, Bredella MA, Freedman L. et al. Marrow fat and preadipocyte factor-1 levels decrease with recovery in women with anorexia nervosa. J Bone Miner Res 2012; 27: 1864-1871
• 45 Taes Y, Lapauw B, Vandewalle S. et al. Estrogen-specific action on bone geometry and volumetric bone density: Longitudinal observations in an adult with complete androgen insensitivity. Bone 2009; 45: 392-397
• 46 Crandall CJ, Tseng C-H, Karlamangla AS. et al. Serum sex steroid levels and longitudinal changes in bone density in relation to the final menstrual period. J Clin Endocrinol Metab 2013; 98: E654-E663
• 47 Mancini A, Di Segni C, Bruno C. et al. Oxidative stress in adult growth hormone deficiency: Different plasma antioxidant patterns in comparison with metabolic syndrome. Endocrine 2018; 59: 130-136
• 48 Mancini A, Raimondo S, Di Segni C. et al. Comparison of plasma antioxidant levels in middle-aged and old male with idiopatic osteoporosis: Preliminary data. Eur Rev Med Pharmacol Sci 2014; 18: 2013-2019